To study the effect of Vyaghradi Kashay tablet on COVID-19 patients

Phase 2/3

Not yet recruiting

Conditions: Coronavirus as the cause of diseases classified elsewhere,

Registration Number: CTRI/2020/10/028570

Lead Sponsor: Ministry of AYUSH Govt of India

Brief Summary: Coronavirus (COVID-19) is a pandemic started from Wuhan City of China in December 2019, with the case of Pneumonia with unknown cause later on in the mid of January 2020 it was declared as an emergency. There are Numerous studies have been published, establishing evidence and opinion-based guides current COVID-19 pandemic, which has taken the world by storm. The sudden outbreak of COVID-19 making society of the people realizes the threat of communicable diseases to human being. A whole-of-society approach is needed to tackle 21st century epidemics so that all the different type of epidemic disease is to be taken into consideration. Genetics and biological factors, ecology and the physical environment; are also affecting causes. This increasing convergence of many factors that requires multi-disciplinary, multi-sectoral and multi-faceted approaches. Ayurved can be helpful in pandemic disease like COVID-19. In COVID patients Cough and sputum, Chest tightness, Difficulty breathing, Fever, Fatigue, Nasal congestion, runny nose, Sick and vomiting are the common symptoms. Vyaghradi Kashaya is indicated in Vatshleshmak jwara having the symptoms like cough, running nose, breathlessness. Therefore, the proposed study is designed to search out the effectiveness of Vaghradi Kashay in asymptomatic and mild to moderate cases of COVID-19. The composition of the drug is Kantakari (*Solanum xanthocarpum*), Sunthi (*Zingiber officinale*), Amruta (*Tinospora cordifolia*), Pippali (*Piper longum*).These drugs have antiviral, antibacterial, antioxidant and immunomodulator property.

Detailed Description: Not available

Recruitment & Eligibility

Status: Not Yet Recruiting

Sex: All

Target Recruitment: 30

Inclusion Criteria

People who have been tested positive to be infected with SARS-CoV2 virus and presenting with no symptoms or with mild to moderate symptoms.
All the patients of age group 18-65 yrs All those who are willing to give written consent for participation in the study.

Exclusion Criteria

COVID patients with symptoms classified as severe or critical.
Persons with severe primary respiratory disease or other pneumonia Pregnant and lactating women Persons with serious complications of diseases such as cancer, heart disease, stroke, disabilities, mental illnesses, etc., and who are considered to be excluded from the study as evaluated by the investigators COVID-19 positive cases participating as subjects in the interventional arm of other COVID-19 clinical trials.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time taken to be tested negative for SARS-CoV2 in RT-PCR.	a)RT PCR 7th and 14th Day \| b)Assessment of clinical recovery at baseline, Daily 7-14 days
To Assess the effect of drug in preventing the progression of severity of symptoms.	a)RT PCR 7th and 14th Day \| b)Assessment of clinical recovery at baseline, Daily 7-14 days

Secondary Outcome Measures

Name	Time	Method
Secondary outcome-	To assess the effect of Vyaghradi Kwath Tab on blood parameters specific to Covid-19.

Trial Locations

Locations (1): A and U Tibbia College and Hospital Govt of NCT of Delhi
🇮🇳
Delhi, DELHI, India
A and U Tibbia College and Hospital Govt of NCT of Delhi
🇮🇳Delhi, DELHI, India
Dr Nitin Jindal
Principal investigator
9354925045
nitjin2005@gmail.com